Selected research
Industry Research
Metabotropic Glutamate Receptor 2 Industry Research Report 2026
Market perspective
The global Metabotropic Glutamate Receptor 2 market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Metabotropic Glutamate Receptor 2 is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Metabotropic Glutamate Receptor 2 is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Metabotropic Glutamate Receptor 2 is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Metabotropic Glutamate Receptor 2 include Johnson & Johnson, Merck & Co Inc, Eli Lilly and Company, Domain Therapeutics SA, Denovo Biopharma LLC, Bristol-Myers Squibb Company and Addex Therapeutics Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Metabotropic Glutamate Receptor 2 market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Metabotropic Glutamate Receptor 2 Market by Company
Johnson & Johnson
Merck & Co Inc
Eli Lilly and Company
Domain Therapeutics SA
Denovo Biopharma LLC
Bristol-Myers Squibb Company
Addex Therapeutics Ltd
Metabotropic Glutamate Receptor 2 Segment by Type
LY-2607540
JNJ-40411813
DT-2442
BMT-133218
Others
Metabotropic Glutamate Receptor 2 Segment by Application
Depression
Chronic Pain
Schizophrenia
Anxiety Disorders
Others
Metabotropic Glutamate Receptor 2 Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Metabotropic Glutamate Receptor 2 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Metabotropic Glutamate Receptor 2 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Metabotropic Glutamate Receptor 2.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Metabotropic Glutamate Receptor 2 manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Metabotropic Glutamate Receptor 2 by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Metabotropic Glutamate Receptor 2 in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- LY-2607540
- JNJ-40411813
- DT-2442
- BMT-133218
- Others
Applications
- Depression
- Chronic Pain
- Schizophrenia
- Anxiety Disorders
- Others
Companies covered
- Johnson & Johnson
- Merck & Co Inc
- Eli Lilly and Company
- Domain Therapeutics SA
- Denovo Biopharma LLC
- Bristol-Myers Squibb Company
- Addex Therapeutics Ltd
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Metabotropic Glutamate Receptor 2 Market Size (2021-2032)
- 2.2.2 Global Metabotropic Glutamate Receptor 2 Sales (2021-2032)
- 2.2.3 Global Metabotropic Glutamate Receptor 2 Market Average Price (2021-2032)
- 2.3 Metabotropic Glutamate Receptor 2 by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 LY-2607540
- 2.3.3 JNJ-40411813
- 2.3.4 DT-2442
- 2.3.5 BMT-133218
- 2.3.6 Others
- 2.4 Metabotropic Glutamate Receptor 2 by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Depression
- 2.4.3 Chronic Pain
- 2.4.4 Schizophrenia
- 2.4.5 Anxiety Disorders
- 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Metabotropic Glutamate Receptor 2 Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Metabotropic Glutamate Receptor 2 Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Metabotropic Glutamate Receptor 2 Revenue of Manufacturers (2021-2026)
- 3.4 Global Metabotropic Glutamate Receptor 2 Average Price by Manufacturers (2021-2026)
- 3.5 Global Metabotropic Glutamate Receptor 2 Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Metabotropic Glutamate Receptor 2, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Metabotropic Glutamate Receptor 2, Product Type & Application
- 3.8 Global Manufacturers of Metabotropic Glutamate Receptor 2, Established Date
- 3.9 Global Metabotropic Glutamate Receptor 2 Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Johnson & Johnson
- 4.1.1 Johnson & Johnson Company Information
- 4.1.2 Johnson & Johnson Business Overview
- 4.1.3 Johnson & Johnson Metabotropic Glutamate Receptor 2 Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Johnson & Johnson Metabotropic Glutamate Receptor 2 Product Portfolio
- 4.1.5 Johnson & Johnson Recent Developments
- 4.2 Merck & Co Inc
- 4.2.1 Merck & Co Inc Company Information
- 4.2.2 Merck & Co Inc Business Overview
- 4.2.3 Merck & Co Inc Metabotropic Glutamate Receptor 2 Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Merck & Co Inc Metabotropic Glutamate Receptor 2 Product Portfolio
- 4.2.5 Merck & Co Inc Recent Developments
- 4.3 Eli Lilly and Company
- 4.3.1 Eli Lilly and Company Company Information
- 4.3.2 Eli Lilly and Company Business Overview
- 4.3.3 Eli Lilly and Company Metabotropic Glutamate Receptor 2 Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Eli Lilly and Company Metabotropic Glutamate Receptor 2 Product Portfolio
- 4.3.5 Eli Lilly and Company Recent Developments
- 4.4 Domain Therapeutics SA
- 4.4.1 Domain Therapeutics SA Company Information
- 4.4.2 Domain Therapeutics SA Business Overview
- 4.4.3 Domain Therapeutics SA Metabotropic Glutamate Receptor 2 Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Domain Therapeutics SA Metabotropic Glutamate Receptor 2 Product Portfolio
- 4.4.5 Domain Therapeutics SA Recent Developments
- 4.5 Denovo Biopharma LLC
- 4.5.1 Denovo Biopharma LLC Company Information
- 4.5.2 Denovo Biopharma LLC Business Overview
- 4.5.3 Denovo Biopharma LLC Metabotropic Glutamate Receptor 2 Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Denovo Biopharma LLC Metabotropic Glutamate Receptor 2 Product Portfolio
- 4.5.5 Denovo Biopharma LLC Recent Developments
- 4.6 Bristol-Myers Squibb Company
- 4.6.1 Bristol-Myers Squibb Company Company Information
- 4.6.2 Bristol-Myers Squibb Company Business Overview
- 4.6.3 Bristol-Myers Squibb Company Metabotropic Glutamate Receptor 2 Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Bristol-Myers Squibb Company Metabotropic Glutamate Receptor 2 Product Portfolio
- 4.6.5 Bristol-Myers Squibb Company Recent Developments
- 4.7 Addex Therapeutics Ltd
- 4.7.1 Addex Therapeutics Ltd Company Information
- 4.7.2 Addex Therapeutics Ltd Business Overview
- 4.7.3 Addex Therapeutics Ltd Metabotropic Glutamate Receptor 2 Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Addex Therapeutics Ltd Metabotropic Glutamate Receptor 2 Product Portfolio
- 4.7.5 Addex Therapeutics Ltd Recent Developments
5 Global Metabotropic Glutamate Receptor 2 Market Scenario by Region
- 5.1 Global Metabotropic Glutamate Receptor 2 Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Metabotropic Glutamate Receptor 2 Sales by Region: 2021-2032
- 5.2.1 Global Metabotropic Glutamate Receptor 2 Sales by Region: 2021-2026
- 5.2.2 Global Metabotropic Glutamate Receptor 2 Sales by Region: 2027-2032
- 5.3 Global Metabotropic Glutamate Receptor 2 Revenue by Region: 2021-2032
- 5.3.1 Global Metabotropic Glutamate Receptor 2 Revenue by Region: 2021-2026
- 5.3.2 Global Metabotropic Glutamate Receptor 2 Revenue by Region: 2027-2032
- 5.4 North America Metabotropic Glutamate Receptor 2 Market Facts & Figures by Country
- 5.4.1 North America Metabotropic Glutamate Receptor 2 Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Metabotropic Glutamate Receptor 2 Sales by Country (2021-2032)
- 5.4.3 North America Metabotropic Glutamate Receptor 2 Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Metabotropic Glutamate Receptor 2 Market Facts & Figures by Country
- 5.5.1 Europe Metabotropic Glutamate Receptor 2 Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Metabotropic Glutamate Receptor 2 Sales by Country (2021-2032)
- 5.5.3 Europe Metabotropic Glutamate Receptor 2 Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Metabotropic Glutamate Receptor 2 Market Facts & Figures by Country
- 5.6.1 Asia Pacific Metabotropic Glutamate Receptor 2 Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Metabotropic Glutamate Receptor 2 Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Metabotropic Glutamate Receptor 2 Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Metabotropic Glutamate Receptor 2 Market Facts & Figures by Country
- 5.7.1 South America Metabotropic Glutamate Receptor 2 Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Metabotropic Glutamate Receptor 2 Sales by Country (2021-2032)
- 5.7.3 South America Metabotropic Glutamate Receptor 2 Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Metabotropic Glutamate Receptor 2 Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Metabotropic Glutamate Receptor 2 Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Metabotropic Glutamate Receptor 2 Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Metabotropic Glutamate Receptor 2 Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Metabotropic Glutamate Receptor 2 Sales by Type (2021-2032)
- 6.1.1 Global Metabotropic Glutamate Receptor 2 Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Metabotropic Glutamate Receptor 2 Sales Market Share by Type (2021-2032)
- 6.2 Global Metabotropic Glutamate Receptor 2 Revenue by Type (2021-2032)
- 6.2.1 Global Metabotropic Glutamate Receptor 2 Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Metabotropic Glutamate Receptor 2 Revenue Market Share by Type (2021-2032)
- 6.3 Global Metabotropic Glutamate Receptor 2 Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Metabotropic Glutamate Receptor 2 Sales by Application (2021-2032)
- 7.1.1 Global Metabotropic Glutamate Receptor 2 Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Metabotropic Glutamate Receptor 2 Sales Market Share by Application (2021-2032)
- 7.2 Global Metabotropic Glutamate Receptor 2 Revenue by Application (2021-2032)
- 7.2.1 Global Metabotropic Glutamate Receptor 2 Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Metabotropic Glutamate Receptor 2 Revenue Market Share by Application (2021-2032)
- 7.3 Global Metabotropic Glutamate Receptor 2 Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Metabotropic Glutamate Receptor 2 Value Chain Analysis
- 8.1.1 Metabotropic Glutamate Receptor 2 Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Metabotropic Glutamate Receptor 2 Production Mode & Process
- 8.2 Metabotropic Glutamate Receptor 2 Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Metabotropic Glutamate Receptor 2 Distributors
- 8.2.3 Metabotropic Glutamate Receptor 2 Customers
9 Global Metabotropic Glutamate Receptor 2 Analyzing Market Dynamics
- 9.1 Metabotropic Glutamate Receptor 2 Industry Trends
- 9.2 Metabotropic Glutamate Receptor 2 Industry Drivers
- 9.3 Metabotropic Glutamate Receptor 2 Industry Opportunities and Challenges
- 9.4 Metabotropic Glutamate Receptor 2 Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst